Lab
Bon Secours ST Mary's Hospital of Richmond LLC
Bon Secours ST Mary's Hospital of Richmond LLC was paid $208K by Medicaid between Nov 2019 and Dec 2024, across 50 billing codes. Its largest line is 80050, General health panel — 14% of everything it billed.
33Billing provider infoBON SECOURS ST MARY'S HOSPITAL OF RICHMOND LLC
RICHMOND, VA 23226
RICHMOND, VA 23226
33aNPI1588129480assigned 02/05/2019
33bProvider typeClinical Medical Laboratory
28Total paid$208K
24GClaims68,963
24DCodes billed50
24AFirst – last monthNov 2019 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Virginia
Rank by total paid#32 of 78
Median peer was paid$37K
This provider vs. median5.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RALSTON, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 945 | $1K | |
| 2020 | 3,795 | $8K | |
| 2021 | 13,075 | $41K | |
| 2022 | 7,431 | $23K | |
| 2023 | 21,803 | $57K | |
| 2024incomplete | 21,914 | $78K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80050 | General health panel | 14% | 1,830 | 1,644 | $29K |
| 80061 | Lipid panel | 12% | 7,695 | 6,941 | $26K |
| 80053 | Comprehensive metabolic panel | 11% | 7,801 | 7,078 | $22K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 9.9% | 2,355 | 2,134 | $21K |
| 84443 | Thyroid stimulating hormone (TSH) | 6.4% | 3,550 | 3,211 | $13K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 6.3% | 1,755 | 1,555 | $13K |
| 83036 | Hemoglobin; glycosylated (A1C) | 6.3% | 6,417 | 5,819 | $13K |
| 86803 | 4.1% | 1,998 | 1,772 | $8K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.1% | 4,128 | 3,749 | $8K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 4.0% | 411 | 376 | $8K |
| 85027 | 3.1% | 3,496 | 3,179 | $6K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.0% | 1,771 | 1,643 | $4K |
38 more codes
| 84439 | 1.6% | 1,429 | $3K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.6% | 195 | $3K |
| 82607 | 1.4% | 693 | $3K | |
| 82570 | 1.2% | 1,715 | $2K | |
| 82728 | 1.2% | 712 | $2K | |
| 82043 | 1.2% | 1,590 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,075 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 142 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 128 | $2K |
| 83550 | <1% | 732 | $2K | |
| 87340 | <1% | 547 | $2K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 288 | $1K |
| 86780 | <1% | 302 | $1K | |
| 83540 | <1% | 773 | $1K | |
| 81001 | <1% | 1,027 | $929.64 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,463 | $872.16 |
| 84153 | <1% | 167 | $704.72 | |
| 82746 | <1% | 152 | $646.80 | |
| 80076 | <1% | 246 | $588.51 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 20 | $500.54 |
| 86706 | <1% | 175 | $369.10 | |
| 83735 | <1% | 195 | $325.62 | |
| 86592 | <1% | 210 | $259.21 | |
| 86704 | <1% | 80 | $150.72 | |
| 87186 | <1% | 54 | $140.25 | |
| 85652 | <1% | 145 | $136.31 | |
| 81003 | <1% | 205 | $129.86 | |
| 82784 | <1% | 15 | $119.04 | |
| 87077 | <1% | 30 | $111.32 | |
| 84403 | <1% | 14 | $90.37 | |
| 85610 | <1% | 74 | $85.65 | |
| 86850 | <1% | 19 | $54.15 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 47 | $52.65 |
| 86140 | <1% | 26 | $49.60 | |
| 87081 | <1% | 16 | $42.46 | |
| 82550 | <1% | 13 | $33.88 | |
| 82950 | <1% | 29 | $32.21 | |
| 82172 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRALSTON, KIMBERLY (SYSTEM DIRECTOR)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.